material information disclosure

Apollo Global Management faces securities class action lawsuit over alleged Epstein disclosure failures. Lead plaintiff deadline set for May 1, 2026.

$QURE plunged 49% after FDA rejected AMT-130 Phase I/II data for accelerated approval. Securities lawsuit filed; lead plaintiff deadline April 13, 2026.

Enphase Energy faces class action lawsuit over failure to disclose inventory management limitations and tax credit risks. Lead plaintiff deadline: April 20, 2026.

Class action lawsuit filed against Enphase Energy alleging securities fraud related to undisclosed channel inventory and tax credit impact concerns between April 2025 and October 2025.

uniQure stock plunges 49% after FDA rejects gene therapy data for AMT-130, triggering securities fraud class action lawsuit for investors trading September-October 2025.

Corcept Therapeutics stock plummeted 50% after FDA rejected lead drug relacorilant. Investors allege prior misleading statements about approval likelihood.

BellRing Brands faces securities fraud lawsuit after 52% stock decline tied to undisclosed inventory issues and weak guidance, with investor deadline March 23, 2026.

Ultragenyx faces securities lawsuit over delayed disclosure of failed Phase 3 trial. Investors must file lead plaintiff claims by April 6, 2026.

Corcept faces securities lawsuit after FDA rejected its drug candidate, causing 50% stock drop. Investors must apply by April 21 for class action lead plaintiff status.

uniQure faces class action lawsuit over failing to disclose FDA rejection of AMT-130 drug candidate, causing 49% stock decline. Lead plaintiff deadline: April 13, 2026.

uniQure faces securities fraud lawsuit after FDA rejected its drug candidate AMT-130, causing a 49% stock plunge. Plaintiffs allege the company failed to disclose material information to investors.

Corcept Therapeutics faces securities fraud lawsuit for failing to disclose FDA setback on relacorilant drug, causing 50% stock decline.

Law firm files securities fraud lawsuit against BellRing after 52% stock plunge, alleging failure to disclose inventory and supply chain issues.

Securities class action filed against Enphase Energy for allegedly misleading statements on inventory and tax credits. Claim deadline April 2026.

Ultragenyx faces securities lawsuit after failing to disclose setrusumab trial failure, causing 42% stock drop. Investors claim company withheld material information before December announcement.

uniQure faces securities lawsuit over failing to disclose that FDA rejected its gene therapy candidate AMT-130, causing stock to plunge 49%. Lead plaintiff deadline set for April 13, 2026.

BellRing Brands faces securities lawsuit for failing to disclose material information about business challenges between November 2024 and August 2025, leading to significant stock declines.

uniQure stock plummeted 49% after FDA rejected accelerated approval for gene therapy AMT-130, triggering a class action lawsuit alleging securities fraud.

BellRing Brands faces securities fraud lawsuit for allegedly failing to disclose significant inventory issues. Stock fell 52% during the class period amid operational challenges.